Susan D. DeVore
Susan D. DeVore's purchase track record
Susan D. DeVore has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/19/2025 | ELV | $375K | +4.6% | +11.7% | +6.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Elevance Health Q3 Outlook: Premium Pressures and Sector Peer Trends. Elevance Health is preparing for its third-quarter earnings report, with analysts examining key metrics and the potential impact of lower premiums on the company's results. Broader sector news highlights peers like UnitedHealth, Centene, and Oscar Health pursuing growth and cost-saving strategies amidst shifting premium dynamics. The market is observing how these competitive and industry-wide pressures will align with Elevance Health's upcoming performance.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Solventum Featured in Yahoo’s Overrated and Profitable Stock Lists. Yahoo highlighted Solventum in two recent articles. In one piece it was listed among stocks that may be overvalued, while the other article named it a profitable long‑term option. The coverage may influence how investors view the company’s valuation and growth prospects. The stock remains near the middle of its 52‑week range.
Transaction History
| UNM | ▲ Buy | Grant | 2,191 | $0 | 5/26/2026 | View on chart |
| ELV | ▲ Buy | Grant | 563 | $0 | 5/13/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 3,403 | $0 | 4/30/2026 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 1,980 | $0 | 3/27/2026 | View on chart |
| ELV | ▲ Buy | Open Market | 1,200 | $375K | 8/19/2025 | View on chart |
| UNM | ▲ Buy | Grant | 2,198 | $0 | 5/22/2025 | View on chart |
| ELV | ▲ Buy | Grant | 601 | $0 | 5/14/2025 | View on chart |
| SOLV | ▲ Buy | Option Exercise | 3,564 | $0 | 5/13/2025 | View on chart |
| UNM | ▼ Sell | Open Market | 5,577 | $450K | 3/3/2025 | View on chart |
| UNM | ▼ Sell | Open Market | 4,423 | $359K | 3/3/2025 | View on chart |
| UNM | ▲ Buy | Grant | 3,342 | $0 | 5/23/2024 | View on chart |
| ELV | ▲ Buy | Grant | 388 | $0 | 5/15/2024 | View on chart |
| UNM | ▲ Buy | Grant | 3,839 | $0 | 5/25/2023 | View on chart |
| ELV | ▲ Buy | Grant | 457 | $0 | 5/10/2023 | View on chart |
| UNM | ▲ Buy | Grant | 4,448 | $0 | 5/26/2022 | View on chart |
| ELV | ▲ Buy | Grant | 440 | $0 | 5/18/2022 | View on chart |
| ELV | ▲ Buy | Grant | 416 | $0 | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Unum Group featured in duration hedging stock list
Unum Group was included in a recent Yahoo Finance article discussing U.S. stocks relevant to duration hedging and interest rate risk. This highlights the company's sensitivity to interest rate movements, a key factor for insurers. With the stock trading near its 52-week low, this news underscores the ongoing market focus on how rate changes may impact Unum's financial performance.
Unum Group featured in duration hedging stock list. Unum Group was included in a recent Yahoo Finance article discussing U.S. stocks relevant to duration hedging and interest rate risk. This highlights the company's sensitivity to interest rate movements, a key factor for insurers. With the stock trading near its 52-week low, this news underscores the ongoing market focus on how rate changes may impact Unum's financial performance.